• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Mannatech Reports Financial Results for Fourth Quarter and Full Year 2023

    3/28/24 7:00:00 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email

    Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter and year ended December 31, 2023.

    Fourth Quarter Highlights

    • Fourth quarter 2023 net sales were $32.7 million, a decrease of $1.6 million, or 4.7%, as compared to $34.3 million in the fourth quarter of 2022.
    • Gross profit as a percentage of net sales improved to 75.4% as compared to 69.0% for the same period in 2022. Reduced supply chain shipping costs more than offset price increases in certain raw materials.
    • Operating loss in the fourth quarter was $0.9 million, improved from an operating loss of $2.7 million in the fourth quarter of 2022.
    • Net loss was $1.8 million, or $0.94 per diluted share, for the fourth quarter 2023, as compared to net loss of $6.5 million, or $3.50 per diluted share, for the fourth quarter 2022.

    J. Stanley Fredrick, Chairman of the Board of Mannatech, stated, "Demand remained weak in the fourth quarter as reflected in our sales decline from last year's fourth quarter. However, our revenues were essentially flat to our third quarter this year. Although we incurred an operating loss in the current quarter, we mitigated our loss through active supply chain management and reduction of selling and administrative expenses."

    "We incurred a foreign exchange loss of approximately $1.0 million in the fourth quarter, reflected in 'Other Expense' in our Statement of Operations. We had a similar experience in the fourth quarter last year. We are a multinational company and therefore we are subject to fluctuations in the value of the U.S. Dollar versus other currencies in the countries we operate. These losses had a significant impact on our net loss in the fourth quarter of this year and last year," said Mr. Fredrick.

    Total Year 2023 Highlights

    • Net sales for the year ended December 31, 2023 was $132.0 million, as compared to $137.2 million for the year ended December 31, 2022. Net sales decreased $5.2 million, or 3.8%, for 2023, as compared to 2022. Our 2023 net sales were unfavorably affected by $2.3 million due to the effect of foreign exchange rates. Excluding this impact, Net Sales on a Constant dollar basis (see Non-GAAP Financial Measures, below) declined $2.9 million, or 2.1%, as compared to 2022 GAAP net sales.
    • Operating loss was $1.0 million for the year ended December 31, 2023, as compared to $0.4 million for the same period last year. Our 2023 operating loss, on a Constant dollar basis (see Non-GAAP Financial Measures, below), was $0.4 million.
    • In June 2023, the Company launched a tiered affiliate program in the United States under the brand name, "Trulu™." The Trulu brand is operated by our wholly owned subsidiary, "NEMO", and is separate from our network marketing business. For the year ended December 31, 2023, we incurred an operating loss of $1.1 million in connection with the start-up of our NEMO business.

    Excluding the startup loss of NEMO from the consolidated operating loss on a Constant dollar basis, we would have generated an operating profit of approximately $0.7 million in 2023, as compared to an operating loss of $0.4 million in 2022.

    • Net loss for 2023 was $2.2 million, or $1.20 per diluted share, as compared to net loss of $4.5 million, or $2.35 per diluted share, for 2022.
    • As of December 31, 2023, the company's cash and cash equivalents decreased to $7.7 million from $13.8 million as of December 31, 2022. Operating the business was a use of $2.4 million in cash. The company invested approximately $0.7 million in back-office software projects and equipment, reported as property and equipment. It used $1.0 million to pay long-term liabilities and finance lease obligations. Finally, shareholder value was returned with $0.7 million for dividends to shareholders and the Company repurchased $0.2 million in common stock.
    • The approximate number of new and continuing independent associate and preferred customer positions held by individuals in Mannatech's network and associated with purchases of its packs or products as of December 31, 2023 and 2022 remained constant at approximately 145,000. Recruiting increased 4.4% in the fourth quarter of 2023 as compared to the fourth quarter of 2022. The number of new independent associate and preferred customer positions in the company's network for the fourth quarter of 2023 was 18,156 as compared to 17,398 in 2022.

    "Careful supply chain cost controls, price adjustments and favorable product mix contributed to a 210 basis point improvement in gross profit margin in the current year as compared to last year," said Mr. Fredrick.

    Mr. Fredrick continued, "We overcame economic challenges throughout our world-wide footprint in 2023, as well as issues and significant start-up costs related to a new product launch. We believe we are emerging from the severe economic decline of the past few years and the long-term outlook for our business is favorable. In the short term, we expect that we will continue to face challenges of a slow rate of growth in demand in certain markets we operate while other regions will recover at a faster rate. However, we are resolved to continue to focus on growing our customer and associate base, as well as improving our revenues and profitability in 2024."

    Non-GAAP Measures

    In addition to results presented in accordance with GAAP, this press release and related tables include certain non-GAAP financial measures, including a presentation of constant dollar measures. The company discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations.

    The company believes that these non-GAAP financial measures provide useful information to investors because they are an indicator of the strength and performance of ongoing business operations. The constant currency figures are financial measures used by management to provide investors an additional perspective on trends. Although it believes the non-GAAP financial measures enhance investors' understanding of their business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. Please see the accompanying table entitled "Non-GAAP Financial Measures" for a reconciliation of these non-GAAP financial measures.

    Safe Harbor statement

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "may," "will," "should," "hope," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "approximates," "predicts," "projects," "potential," and "continues" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, the impact of COVID-19 on Mannatech's business, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

    Individuals interested in Mannatech's products or in exploring its business opportunity can learn more at Mannatech.com.

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS

    (in thousands, except share information)

     

     

    December 31,

    2023

     

    December 31,

    2022

    ASSETS

     

     

     

    Cash and cash equivalents

    $

    7,731

     

     

    $

    13,777

     

    Restricted cash

     

    938

     

     

     

    944

     

    Accounts receivable, net of allowance of $1,278 and $973 in 2023 and 2022, respectively

     

    91

     

     

     

    218

     

    Income tax receivable

     

    465

     

     

     

    423

     

    Inventories, net

     

    14,535

     

     

     

    14,726

     

    Prepaid expenses and other current assets

     

    1,774

     

     

     

    2,389

     

    Deferred commissions

     

    2,130

     

     

     

    2,476

     

    Total current assets

     

    27,664

     

     

     

    34,953

     

    Property and equipment, net

     

    4,147

     

     

     

    3,759

     

    Long-term restricted cash

     

    718

     

     

     

    476

     

    Other assets

     

    7,066

     

     

     

    8,439

     

    Deferred tax assets, net

     

    1,611

     

     

     

    1,501

     

    Total assets

    $

    41,206

     

     

    $

    49,128

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

    Current portion of finance leases

    $

    269

     

     

    $

    61

     

    Accounts payable

     

    4,010

     

     

     

    4,361

     

    Accrued expenses

     

    6,779

     

     

     

    7,510

     

    Commissions and incentives payable

     

    8,175

     

     

     

    9,256

     

    Taxes payable

     

    1,521

     

     

     

    3,281

     

    Current notes payable

     

    240

     

     

     

    263

     

    Deferred revenue

     

    4,786

     

     

     

    5,106

     

    Total current liabilities

     

    25,780

     

     

     

    29,838

     

    Finance leases, excluding current portion

     

    956

     

     

     

    88

     

    Other long-term liabilities

     

    3,986

     

     

     

    5,026

     

    Total liabilities

     

    30,722

     

     

     

    34,952

     

    Commitments and contingencies (Note 11)

     

     

     

    Shareholders' equity:

     

     

     

    Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding

     

    —

     

     

     

    —

     

    Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and 1,860,154 shares outstanding as of December 31, 2023 and 2,742,857 shares issued and 1,858,800 shares outstanding as of December 31, 2022

     

    —

     

     

     

    —

     

    Additional paid-in capital

     

    33,309

     

     

     

    33,377

     

    Retained earnings (accumulated deficit)

     

    (1,301

    )

     

     

    1,686

     

    Accumulated other comprehensive (loss)

     

    (1,015

    )

     

     

    (208

    )

    Treasury stock, at average cost, 882,703 shares as of December 31, 2023 and 884,057 shares as of December 31, 2022

     

    (20,509

    )

     

     

    (20,679

    )

    Total shareholders' equity

     

    10,484

     

     

     

    14,176

     

    Total liabilities and shareholders' equity

    $

    41,206

     

     

    $

    49,128

     

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share information)

     

     

    For the three months ended December 31

     

    For the years ended December 31

     

    2023

     

    2022

     

    2023

     

    2022

     

    $000

     

    %

     

    $000

     

    %

     

    $000

     

    %

     

    $000

     

    %

    Net sales

    $

    32,694

     

    100.0

    %

     

    $

    34,335

     

    100.0

    %

     

    $

    131,955

     

    100.0

    %

     

    $

    137,208

     

    100.0

    %

    Cost of sales

     

    8,048

     

    24.6

     

     

     

    10,633

     

    31.0

     

     

     

    29,090

     

    22.0

     

     

     

    33,060

     

    24.1

     

    Gross profit

     

    24,646

     

    75.4

     

     

     

    23,702

     

    69.0

     

     

     

    102,865

     

    78.0

     

     

     

    104,148

     

    75.9

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

    Commissions and incentives

     

    13,389

     

    41.0

     

     

     

    13,996

     

    40.8

     

     

     

    53,588

     

    40.6

     

     

     

    55,483

     

    40.4

     

    Selling and administrative expenses

     

    11,748

     

    35.9

     

     

     

    12,078

     

    35.2

     

     

     

    48,613

     

    36.8

     

     

     

    47,443

     

    34.6

     

    Depreciation and amortization

     

    404

     

    1.2

     

     

     

    278

     

    0.8

     

     

     

    1,628

     

    1.2

     

     

     

    1,627

     

    1.2

     

    Total operating expenses

     

    25,541

     

    78.1

     

     

     

    26,352

     

    76.8

     

     

     

    103,829

     

    78.7

     

     

     

    104,553

     

    76.2

     

    Income (loss) from operations

     

    (895

    )

    (2.7

    )

     

     

    (2,650

    )

    (7.7

    )

     

     

    (964

    )

    (0.7

    )

     

     

    (405

    )

    (0.3

    )

    Interest income

     

    7

     

    —

     

     

     

    31

     

    0.1

     

     

     

    4

     

    —

     

     

     

    88

     

    0.1

     

    Other expense, net

     

    (973

    )

    (3.0

    )

     

     

    (450

    )

    (1.3

    )

     

     

    (170

    )

    (0.1

    )

     

     

    (162

    )

    (0.1

    )

    Income before income taxes

     

    (1,861

    )

    (5.7

    )

     

     

    (3,069

    )

    (8.9

    )

     

     

    (1,130

    )

    (0.9

    )

     

     

    (479

    )

    (0.3

    )

    Income tax (provision) benefit

     

    105

     

    0.3

     

     

     

    (3,440

    )

    (10.0

    )

     

     

    (1,109

    )

    (0.8

    )

     

     

    (4,011

    )

    (2.9

    )

    Net loss

    $

    (1,756

    )

    (5.4

    )%

     

    $

    (6,509

    )

    (19.0

    )%

     

    $

    (2,239

    )

    (1.7

    )%

     

    $

    (4,490

    )

    (3.3

    )%

    (Loss) per common share:

     

     

     

     

     

     

     

     

     

     

     

    Basic

    $

    (0.94

    )

     

     

    $

    3.50

     

     

     

    $

    (1.20

    )

     

     

    $

    (2.35

    )

     

    Diluted

    $

    (0.94

    )

     

     

    $

    3.50

     

     

     

    $

    (1.20

    )

     

     

    $

    (2.35

    )

     

    Weighted-average common shares outstanding:

     

     

     

     

     

     

     

     

     

    Basic

     

    1,860

     

     

     

     

    1,859

     

     

     

     

    1,866

     

     

     

     

    1,913

     

     

    Diluted

     

    1,860

     

     

     

     

    1,859

     

     

     

     

    1,866

     

     

     

     

    1,913

     

     

    Non-GAAP Financial Measures (Sales, Gross Profit and Income From Operations in Constant Dollars)

    To supplement its financial results presented in accordance with generally accepted accounting principles in the United States ("GAAP"), Mannatech discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations. It refers to these adjusted financial measures as constant dollar items, which are non-GAAP financial measures. The company believes these measures provide investors an additional perspective on trends. To exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, it calculates current year results and prior year results at a constant exchange rate, which is the prior year's rate. Currency impact is determined as the difference between actual growth rates and constant currency growth rates.

    The table below reconciles fourth quarter 2023 constant dollar sales to GAAP sales.

     

    Sales - Q4 2023

     

    GAAP

    Measure:

    Total $

     

    Non-GAAP Measure:

    Constant $

     

    Constant $ Change

    Americas

    $

    11.0

     

    $

    10.8

     

    $

    (0.2

    )

    Asia Pacific

    $

    19.4

     

    $

    19.3

     

    $

    (0.1

    )

    EMEA

    $

    2.3

     

    $

    2.4

     

    $

    0.1

     

    Total

    $

    32.7

     

    $

    32.5

     

    $

    (0.2

    )

    The table below reconciles fiscal year 2023 and 2022 constant dollar net sales, gross profit and income from operations to GAAP net sales, gross profit and income from operations.

     

    2023

     

    2022

     

    Constant Dollar Change

     

    GAAP

    Measure:

    Total $

     

    Non-GAAP Translation Adjustment

     

    Non-GAAP Measure:

    Constant $

     

    GAAP

    Measure:

    Total $

     

    Dollar

     

    Percent

    Net sales

    $

    132.0

     

     

    $

    2.3

     

    $

    134.3

     

     

    $

    137.2

     

     

    $

    (2.9

    )

     

    (2.1

    )%

    Gross profit

    $

    102.9

     

     

    $

    1.7

     

    $

    104.6

     

     

    $

    104.1

     

     

    $

    0.5

     

     

    0.5

    %

    Loss from operations

    $

    (1.0

    )

     

    $

    0.6

     

    $

    (0.4

    )

     

    $

    (0.4

    )

     

    $

    —

     

     

    —

    %

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240327903891/en/

    Get the next $MTEX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

      "The Long Run" showcases a world-record journey powered by Glycan Replenishment Therapy and unmatched determination. Global health and wellness innovator Mannatech is proud to premiere Steve Edwards: The Long Run, an 11-minute short documentary chronicling the unbelievable true story of Steve Edwards—an everyday man turned endurance icon. With over 1,000 official marathons completed in record-setting average times, Edwards' legacy is one of resilience, quiet determination and the pursuit of human potential. The film debuts globally today, May 21, and is followed by an in-depth interview with Steve Edwards himself following the documentary. It is available to watch free at events.mannatech.

      5/21/25 12:16:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Fourth Quarter 2024 Financial Results

      Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter of 2024. Quarter End Results Fourth quarter net sales for 2024 were $29.0 million, a decrease of $3.7 million, or 11.3%, as compared to $32.7 million in the fourth quarter of 2023. During the fourth quarter, the company's net sales declined 9.2% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.7 million in net sales as compared to the fourth quarter of 2023. Gross profit as a percentage of net sales improved to 80

      3/26/25 6:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Toth Robert

      4/A - MANNATECH INC (0001056358) (Issuer)

      3/17/25 1:23:48 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Fredrick J Stanley was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 0.76% to 356,975 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:18 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Toth Robert was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 3% to 91,130 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Financials

    Live finance-specific insights

    See more
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Third Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

      11/12/24 4:48:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Second Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply

      8/13/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    SEC Filings

    See more
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      5/13/25 5:06:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Mannatech Incorporated

      10-Q - MANNATECH INC (0001056358) (Filer)

      5/13/25 4:57:24 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Mannatech Incorporated

      DEF 14A - MANNATECH INC (0001056358) (Filer)

      4/22/25 5:01:03 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    See more

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

      Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

      11/26/24 4:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO

      Mannatech, Incorporated (NASDAQ: MTEX) reported that Alfredo (Al) Bala, announced his retirement as the company's CEO effective April 1, 2024. J. Stanley Fredrick, Chairman of the Board of Mannatech, Incorporated stated, "Al will continue to serve the company as an advisor focused on customer acquisition and sales growth. This transition enables Al to work more closely with our associates in the field which has always been his first love. In this new role, Al will also focus on field and leadership development, leveraging his 43 years of experience in direct sales at both the field and corporate level helping to create and develop programs dedicated to growing people and sales." Mr. Fredr

      3/13/24 7:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Mannatech Incorporated

      SC 13G - MANNATECH INC (0001056358) (Subject)

      11/1/24 11:44:29 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      1/13/23 11:03:46 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      2/7/22 6:32:28 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care